Win32 Virus Removal

Rochester NY aEUR" www.shamrockstocks.com names (OTCBB: DLYT | PowerRating) Dais Analytic Corp., (OTCBB: CHDO | PowerRating) CHDT Corp., and (OTCBB: AEMD | PowerRating) Aethlon Medical, Inc. itaEUR(TM)s aEURoeLucky Picks of the Day!

To feature your publicly traded company in our alers email us at info@shamrockstocks.com.

Also, you can receive up to the minute stock alerts via our Twitter page. www.twitter.com/shamrockstocks

aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"-

Visit: www.shamrockstocks.com

About Dais Analytic Corporation

Dais Analytic Corporation (OTCBB: DLYT) is commercializing its nanotechnology materials and processes into break-through products becoming a leading participant in the applied nanotechnology industry with a specialized focus on the needs of the energy and water industries. Products incorporating DaisaEUR(TM)s nanotechnology (www.daisanalytic.com) minimize consumption of irreplaceable natural resources and stop degradation of our environment. To find out more about ConsERV (energy recovery for HVAC) please log onto www.conserv.com.

News Today:

TAMPA, FL, Sep 21, 2010 aEUR" DAIS ANALYTIC CORPORATION (OTCBB: DLYT), a clean technology firm commercializing its nanotechnology inventions focusing on the applications of desalination, energy efficient HVAC equipment, and energy storage (ultracapacitor), announced today it has entered into a research agreement with prestigious University of Florida located in Gainesville, Fl. The agreement will power the path to energyaEUR(TM)s future focusing on DaisaEUR(TM) NanoCap(TM) ultra capacitor moving it from successful materials testing to prototype.

The materials test results, conducted by GEaEUR(TM)s Global Research and Development Center, show DaisaEUR(TM) materials and design exhibit great promise to yield a power storage device able to dramatically improve power delivery from consumer electronics to aEURoesmart gridaEUR applications, to most forms of transportation.

aEURoeNanoCapaEUR(TM)s testing to date shows that our materials have the potential of being configured into an energy storage unit capable of replacing the internal combustion engine aEUR" or perhaps better described, as being able to deliver the electronic equal to the energy density of gasoline,aEUR said Scott Ehrenberg, Chief Technology Officer of Dais. Further, Ehrenberg states, aEURoeThe unit, which we believe can be built and marketed, has the ability to positively improve power delivery in a wide range of industries world-wide.aEUR

With the advent of an energy storage device such as NanoCap, designed to be scalable for small or large projects, electricity from intermittent electricity generators like solar panels and wind turbines could be stored for use at a later time. This form of flexible storage allows the steady and predictable release of renewable electricity into the nationaEUR(TM)s electric grid advancing the economics of renewable energy sources which offer strong environmental positives.

President of Dais, Tim Tangredi stated, aEURoeThe partnership with the University of FloridaaEUR(TM)s strong team, headed by Saeed Moghaddam, Ph.D., is designed to allow Dais to move its aEUR~game changingaEUR(TM) ultracapacitor application closer to market introduction.aEUR

aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"-

Visit: www.shamrockstocks.com

About CHDT Corporation

CHDT Corporation (www.chdtcorp.com) is a public holding Company that engages, through its wholly owned subsidiaries, in the development, manufacturing, logistics, and distribution of consumer products to retailers and wholesalers throughout North America. See www.chdtcorp.com for more information about the Company and also www.capstoneindustries.com for information on our current product offerings. Reference of URLs in this press release does not incorporate said URLs or any of their contents in this press release.

News Today:

DEERFIELD BEACH, FL, Sep 21, 2010 aEUR" South Florida-based Capstone Industries, a wholly owned subsidiary of CHDT Corporation (OTCBB: CHDO), announced its Mini Eco-i-Lite product is now available for the first time at a national office supply chain throughout the holiday season.

The Company has sold its Eco-i-Lite products into grocery, mail order, mass merchandisers, online retailers, specialty retailers, overseas distributors, warehouse clubs and an office supply retailer in 2009. The Mini Eco-i-Lite has gained much popularity over the past year. It is CapstoneaEUR(TM)s smaller version of the Eco-i-Lite series featuring a lithium-powered, multi-function, power failure light. The device includes 3 LED bulbs, an LED nightlight and an induction-charging ring. The unit is environmentally friendly and requires no battery or bulb change making the light affordable to own. The product automatically illuminates when lifted from its charging ring or when a power failure occurs and provides soft nighttime lighting to help users find their way in the dark.

Not only does the Eco-i-Lite provide multiple lighting functions, it is also stylish and pleasing to the eye, eliminating the need to hide it in a drawer or utility area. The Eco-i-LiteaEUR(TM)s aesthetic appeal makes it easy for the homeowner to place it anywhere in the home. Once in plain sight, the Eco-i-Lite remains charged and ready for use when needed.

For more information about the Eco-i-Lite product line, including a list of current retailers, please visit Capstone IndustriesaEUR(TM) website at www.capstoneindustries.com.

About Capstone Industries, Inc.

For more than a decade, the South Florida-based Company Capstone Industries has specialized in the design, production, and distribution of consumer products as a supplier to major retail operations throughout the USA. Capstone Industries is committed to the development and distribution of unique and inventive products to a variety of channels including bookstore chains, convenience stores, drug & grocery, electronics, hardware, home improvement, internet, mail order, mass market, office supply, specialty, and warehouse clubs.

aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"-

Visit: www.shamrockstocks.com

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier(R) is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier(R) captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier(R) can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier(R) to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier(R) as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier(R) in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier(R) has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier(R) provides us with a pipeline into four significant market opportunities:

Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.

Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.

Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.

Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier(R) is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier(R) is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier(R) is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier(R) via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier(R) in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.

News Today

SAN DIEGO, Sept 21, 2010 aEUR" Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier(R) within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats. The Aethlon Hemopurifier(R) is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Based on studies conducted by government and non-government research organizations, Aethlon believes the Hemopurifier(R) represents the most advanced and perhaps the only true broad-spectrum countermeasure against viral threats most likely to be weaponized against civilian and military populations.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

(Photo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

Therapeutics able to target multiple bioterror threats have become a focal point of the U.S. Health and Human Services Department (HHS) and dual-use therapies such as the Hemopurifier(R), that also have commercial applications against established disease conditions such as hepatitis-C virus (HCV) and cancer, are no longer precluded from consideration to be supported by government programs.

aEURoeRevamped government policies expand the opportunity for our Hemopurifier(R) in the United States and improve our potential access to non-dilutive capital resources, which are not capped by the public market value of our organization,aEUR stated Aethlon Chairman and CEO, Jim Joyce. aEURoeWe now plan to update an investigational device exemption (IDE) already submitted to the FDA, which if approved, would allow us to collect further clinical data that potentially could contribute to other infectious disease and cancer studies we hope to initiate in the United States.aEUR

The IDE previously submitted to the FDA by Aethlon specifies the Hemopurifier(R) as a medical device for the single-use removal of bioterror related viruses from circulation. As efficacy studies against such pathogens cannot be conducted in humans, the demonstration of treatment safety represents the primary treatment challenge in humans. While efficacy studies against such threats may not be permissible, Aethlon has demonstrated significant viral load reductions in HIV and HCV infected individuals. In vitro studies have verified that the Hemopurifier(R) has broad-spectrum capabilities against both bioterror and emerging pandemic threats. These studies confirmed the ability of the Hemopurifier(R) to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

The landscape to encourage countermeasure development is rapidly improving. Last month, the Obama administration announced it would seek to improve government efforts to spur development of countermeasures for potential biological-weapon agents and HHS declared that programs intended to prepare the country for biological weapons attacks would be overhauled with a focus toward decreasing the length of time it takes to produce new medical countermeasures, and that new institutes would be established to collaborate with small firms on the production of new treatments. Additionally, funding will be directed to the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) to turn scientific breakthroughs into medical countermeasures. From a regulatory perspective, the FDA has indicated that it will take steps to eliminate obstacles that could slow the pace of the countermeasure review process.

aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"aEUR"-

Visit: www.shamrockstocks.com

About Shamrockstocks.com

Shamrockstocks.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by Shamrockstocks. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

For additional information, please contact info@shamrockstocks.com, www.shamrockstocks.com or www.twitter.com/shamrockstocks.

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (AEMD) AEMD. (AEMD) has Short Term PowerRatings at TradingMarkets. Details on (AEMD) Short Term PowerRatings is available at This Link.

For full details on (CHDO) CHDO. (CHDO) has Short Term PowerRatings at TradingMarkets. Details on (CHDO) Short Term PowerRatings is available at This Link.

For full details on (DLYT) DLYT. (DLYT) has Short Term PowerRatings at TradingMarkets. Details on (DLYT) Short Term PowerRatings is available at This Link.